Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00860743 · ClinicalTrials.gov registry record · Early Phase 1
Respiratory and Autonomic Plasticity Following Intermittent Hypoxia
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 63
- Enrollment target
NCT00860743: Completed Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT00860743 is a Early Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 63 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00860743, a Early Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The prevalence of obstructive sleep apnea is high in the Veteran population. If not treated promptly, sleep apnea may result in daytime fatigue which may lead to increased prevalence of accidents while driving or in the workplace. Recent large scale epidemiological studies have shown that the prevalence of excessive daytime sleepiness increases in individuals who suffer from obstructive sleep apnea. Obstructive sleep apnea may also result in the development of hypertension and other cardiovascular disorders. Previous findings have shown that subjects with sleep apnea have a greater risk for developing coronary vascular disease compared to individuals that do not suffer from sleep apnea Thus, a significant amount of evidence suggests that sleep apnea is a major health concern in the Veteran population. Consequently, determining the mechanisms that may impact on the severity of sleep apnea and increase the prevalence of cardiovascular incidents associated with this disorder is important, as is discovering novel treatments.
Primary Outcome
Ventilation was measured before and after exposure to intermittent hypoxia in males and females. Ventilation was measured using a pneumotachograph, which is a flow measuring device.
Interventions
- DRUG Antioxidant cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-09 |
| Phase | Early Phase 1 |
What the finished NCT00860743 record still lists
NCT00860743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (19% higher).
The record links to 0 conditions, and to 1 intervention - of which Antioxidant cocktail is the first listed.
NCT00860743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00860743 about?
NCT00860743 is a clinical study titled "Respiratory and Autonomic Plasticity Following Intermittent Hypoxia". The prevalence of obstructive sleep apnea is high in the Veteran population. If not treated promptly, sleep apnea may result in daytime fatigue which may lead to increased prevalence of accidents while driving or in the workplace. Recent large scale epidemiological studies have shown that the preval...
What is the current status of trial NCT00860743?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 63 participants. The study started on 2009-09. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00860743?
The interventions under investigation include: Antioxidant cocktail (DRUG).
Who is sponsoring clinical trial NCT00860743?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00860743's enrollment target sits among peer trials
63 388th of 2000 higher than 1,607 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia